ChromaDex® Corporation  announced a $62 million ingredient supply and brand licensing agreement with 5LINX®, a direct marketing company.

January 7, 2014

1 Min Read
ChromaDex Announces $62M Partnership with 5LINX

IRVINE, Calif. ChromaDex® Corporation  announced a $62 million ingredient supply and brand licensing agreement with 5LINX®, a direct marketing company. The four-yearn agreement gives 5LINX marketing rights for ChromaDex's NIAGEN nicotinamide riboside (NR) ingredient for dietary supplements in United States, Canada and Philippines. NIAGEN is the only brand of NR commercially available; published research confirms the niacin ingredient is a precursor to NAD+ in the mitochondria of animals.

Additionally, 5LINX received marketing rights for ChromaDex's PURENERGY ingredient, which combines caffeine and pTeroPure® pterostilbene, for energy-focused dietary supplements.

"The health and wellness stories behind NIAGEN and PURENERGY make each ingredient ideal candidates for us to launch a suite of wellness products that will accelerate the growth in our new wellness segment," said Craig Jerabeck, CEO of 5LINX. "We view this deal as an incredible opportunity for 5LINX to be among the first to offer dietary supplements featuring NIAGEN nicotinamide riboside and PURENERGY."

Earlier this month, ChromaDex announced former Nestle executive Steve Allen would join its board of directors.

Subscribe and receive the latest insights on the health and nutrition industry.
Join 37,000+ members. Yes, it's completely free.

You May Also Like